Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Can Cannabis Cannabinoids Affect Sleep Architecture in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Sleep problems are among the most distressing symptoms for people with dementia and their caregivers. Some researchers have explored whether cannabinoids, compounds found in cannabis such as THC and CBD, might influence sleep architecture, the structure and rhythm of sleep cycles. 

However, according to NHS and NICE guidance, cannabis-based medical products are not recommended for managing sleep disturbance or insomnia in dementia due to limited evidence and unclear safety profiles (NHS Guidance; NICE NG144; NICE NG97). 

Can medical cannabis be accessed legally for women’s health?

What The Research Shows 

Sleep and Cannabinoids in Theory 

Cannabinoids interact with the endocannabinoid system (ECS), which influences circadian rhythms, REM sleep, and the transition between sleep stages. Laboratory research suggests that THC may shorten time to fall asleep, while CBD may stabilise sleep cycles at low doses and disrupt them at higher doses. 

A 2024 review in Nature Reviews Neurology found that cannabinoids can alter REM–non-REM balance and affect melatonin signalling, but these findings were mostly based on animal and non-dementia human studies (Nature Reviews Neurology, 2024). 

Evidence in Dementia 

Clinical trials in dementia show limited and inconsistent results. A 2023 randomised crossover study (n=21) testing THC/CBD formulations in older adults with dementia found no significant improvement in total sleep time or sleep efficiency compared with placebo (PubMed Study, 2023). 

A 2024 Swiss feasibility study observed that some patients fell asleep faster and experienced less night-time restlessness, but results were not statistically significant (Swiss Study, 2024). 

A 2025 systematic review of cannabinoids and sleep in older adults concluded that evidence remains inconclusive, with small studies reporting mixed effects on sleep onset, REM suppression, and night-time wakefulness (PubMed Meta-Analysis, 2025). 

Expert Consensus 

The Johns Hopkins Center for Psychedelic and Consciousness Research stated in 2024 that cannabinoids may modify sleep-related neurotransmitters but that evidence in dementia remains preclinical and speculative (Frontiers in Aging Neuroscience, 2024). 

The Clinical Bottom Line 

  • Cannabinoids can influence sleep mechanisms but are not proven to improve sleep in dementia. 
  • No consistent evidence of better sleep duration, quality, or architecture. 
  • NICE, NHS, WHO, and Johns Hopkins classify findings as preliminary. 
  • Cannabis should not be used for sleep disturbance outside formal research trials. 

Educational Context: AlleviMed 

Educational platforms such as AlleviMed help patients understand how medical cannabis eligibility is assessed in the UK. They clarify that sleep disorders, dementia, and cognitive conditions are not licensed indications for cannabis prescriptions. 

Takeaway 

Although cannabinoids can affect sleep patterns in laboratory settings, no clinical studies show improved sleep architecture in dementia. NHS, NICE, and WHO agree that research remains experimental and that cannabis-based medicines should not be used for dementia-related sleep problems outside controlled trials. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories